Sotera Health Co (SHC) · Insider trading
What Sotera Health's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$2.59B
4 insiders, 0% under a plan
Net, 12 months
−$2.59B
bought less sold
Latest filing
2026-08-19
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Warburg Pincus & Co.Director, 10% owner | – | $2.28B | 10 | 2026-05-13 | – |
| Gtcr CO-Invest Xi LPDirector, 10% owner | – | $760.39M | 5 | 2026-05-13 | – |
| Petras Michael B. Jr.Director, Executive Chairman | – | $33.51M | 5 | 2026-08-17 | 397,912 |
| Rutz Michael PPresident of Sterigenics | – | $4.90M | 2 | 2026-08-07 | 334,279 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | Petras Michael B. Jr.Director, Executive Chairman | Sale | 294,515 | 18.50 | $5.45M | 397,912 | Form 4 |
| 2026-08-17 | Petras Michael B. Jr.Director, Executive Chairman | Saleindirect | 850,000 | 18.50 | $15.72M | 3,969,393 | Form 4 |
| 2026-08-07 | Rutz Michael PPresident of Sterigenics | Sale | 150,000 | 18.84 | $2.83M | 334,279 | Form 4 |
| 2026-05-13 | Gtcr CO-Invest Xi LPDirector, 10% ownerwith Gtcr Fund Xi/a LP, Gtcr Fund Xi/c LP, Gtcr Investment Xi LLC, Gtcr Partners Xi/a&c LP | Saleindirect | 12,735,301 | 15.17 | $193.19M | 0 | Form 4 |
| 2026-05-13 | Warburg Pincus & Co.Director, 10% ownerwith Warburg Pincus Private Equity Xi, L.P., Wp Xi Partners, L.P., Warburg Pincus Private Equity Xi-b, L.P., Warburg Pincus Xi, L.P., Wp Global LLC, Warburg Pincus Xi Partners, L.P., Warburg Pincus Partners II, L.P., Bull Co-Invest L.P., Bull Holdco L.P. | Saleindirect | 19,102,952 | 15.17 | $289.79M | 0 | Form 4 |
| 2026-05-13 | Warburg Pincus & Co.Director, 10% ownerwith Warburg Pincus LLC, Warburg Pincus Private Equity Xi-c, L.P., Warburg Pincus Xi-c, LLC, Warburg Pincus (Cayman) Xi, L.P., Warburg Pincus (Bermuda) Private Equity GP Ltd., Warburg Pincus Partners GP LLC, Warburg Pincus Partners II (Cayman), L.P. | Saleindirect | 19,102,952 | 15.17 | $289.79M | 0 | Form 4 |
| 2026-03-06 | Gtcr CO-Invest Xi LPDirector, 10% ownerwith Gtcr Fund Xi/a LP, Gtcr Fund Xi/c LP, Gtcr Investment Xi LLC, Gtcr Partners Xi/a&c LP | Saleindirect | 10,000,000 | 15.27 | $152.70M | 12,735,301 | Form 4 |
| 2026-03-06 | Warburg Pincus & Co.Director, 10% ownerwith Warburg Pincus Private Equity Xi, L.P., Wp Xi Partners, L.P., Warburg Pincus Private Equity Xi-b, L.P., Warburg Pincus Xi, L.P., Wp Global LLC, Warburg Pincus Xi Partners, L.P., Warburg Pincus Partners II, L.P., Bull Co-Invest L.P., Bull Holdco L.P. | Saleindirect | 15,000,000 | 15.27 | $229.05M | 19,102,952 | Form 4 |
| 2026-03-06 | Warburg Pincus & Co.Director, 10% ownerwith Warburg Pincus LLC, Warburg Pincus Private Equity Xi-c, L.P., Warburg Pincus Xi-c, LLC, Warburg Pincus (Cayman) Xi, L.P., Warburg Pincus (Bermuda) Private Equity GP Ltd., Warburg Pincus Partners GP LLC, Warburg Pincus Partners II (Cayman), L.P. | Saleindirect | 15,000,000 | 15.27 | $229.05M | 19,102,952 | Form 4 |
| 2025-12-08 | Petras Michael B. Jr.Director, Chairman & CEO | Sale | 315,896 | 16.45 | $5.20M | 552,790 | Form 4 |
| 2025-12-08 | Petras Michael B. Jr.Director, Chairman & CEO | Saleindirect | 394,861 | 16.45 | $6.50M | 4,819,393 | Form 4 |
| 2025-12-08 | Petras Michael B. Jr.Director, Chairman & CEO | Saleindirect | 39,243 | 16.45 | $645,547 | 0 | Form 4 |
| 2025-12-03 | Gtcr CO-Invest Xi LPDirector, 10% ownerwith Gtcr Fund Xi/a LP, Gtcr Fund Xi/c LP, Gtcr Investment Xi LLC, Gtcr Partners Xi/a&c LP | Saleindirect | 6,480,000 | 16.33 | $105.82M | 22,735,301 | Form 4 |
| 2025-12-03 | Warburg Pincus & Co.Director, 10% ownerwith Warburg Pincus LLC, Warburg Pincus Private Equity Xi-c, L.P., Warburg Pincus Xi-c, LLC, Warburg Pincus (Cayman) Xi, L.P., Warburg Pincus (Bermuda) Private Equity GP Ltd., Warburg Pincus Partners GP LLC, Warburg Pincus Partners II (Cayman), L.P. | Saleindirect | 9,720,000 | 16.33 | $158.73M | 34,102,952 | Form 4 |
| 2025-12-03 | Warburg Pincus & Co.Director, 10% ownerwith Warburg Pincus LLC, Warburg Pincus Private Equity Xi-c, L.P., Warburg Pincus Xi-c, LLC, Warburg Pincus (Cayman) Xi, L.P., Warburg Pincus (Bermuda) Private Equity GP Ltd., Warburg Pincus Partners GP LLC, Warburg Pincus Partners II (Cayman), L.P. | Saleindirect | 9,720,000 | 16.33 | $158.73M | 34,102,952 | Form 4 |
| 2025-11-10 | Gtcr CO-Invest Xi LPDirector, 10% ownerwith Gtcr Fund Xi/a LP, Gtcr Fund Xi/c LP, Gtcr Investment Xi LLC, Gtcr Partners Xi/a&c LP | Saleindirect | 12,000,000 | 15.65 | $187.80M | 29,215,301 | Form 4 |
| 2025-11-10 | Warburg Pincus & Co.Director, 10% ownerwith Warburg Pincus Private Equity Xi, L.P., Wp Xi Partners, L.P., Warburg Pincus Private Equity Xi-b, L.P., Warburg Pincus Xi, L.P., Wp Global LLC, Warburg Pincus Xi Partners, L.P., Warburg Pincus Partners II, L.P., Bull Co-Invest L.P., Bull Holdco L.P. | Saleindirect | 18,000,000 | 15.65 | $281.70M | 43,822,952 | Form 4 |
| 2025-11-10 | Warburg Pincus & Co.Director, 10% ownerwith Warburg Pincus LLC, Warburg Pincus Private Equity Xi-c, L.P., Warburg Pincus Xi-c, LLC, Warburg Pincus (Cayman) Xi, L.P., Warburg Pincus (Bermuda) Private Equity GP Ltd., Warburg Pincus Partners GP LLC, Warburg Pincus Partners II (Cayman), L.P. | Saleindirect | 18,000,000 | 15.65 | $281.70M | 43,822,952 | Form 4 |
| 2025-09-05 | Gtcr CO-Invest Xi LPDirector, 10% ownerwith Gtcr Fund Xi/a LP, Gtcr Fund Xi/c LP, Gtcr Investment Xi LLC, Gtcr Partners Xi/a&c LP | Saleindirect | 8,000,000 | 15.11 | $120.88M | 41,215,301 | Form 4 |
| 2025-09-05 | Warburg Pincus & Co.Director, 10% ownerwith Warburg Pincus Private Equity Xi, L.P., Wp Xi Partners, L.P., Warburg Pincus Private Equity Xi-b, L.P., Warburg Pincus Xi, L.P., Wp Global LLC, Warburg Pincus Xi Partners, L.P., Warburg Pincus Partners II, L.P., Bull Co-Invest L.P., Bull Holdco L.P. | Saleindirect | 12,000,000 | 15.11 | $181.32M | 61,822,952 | Form 4 |
| 2025-09-05 | Warburg Pincus & Co.Director, 10% ownerwith Warburg Pincus LLC, Warburg Pincus Private Equity Xi-c, L.P., Warburg Pincus Xi-c, LLC, Warburg Pincus (Cayman) Xi, L.P., Warburg Pincus (Bermuda) Private Equity GP Ltd., Warburg Pincus Partners GP LLC, Warburg Pincus Partners II (Cayman), L.P. | Saleindirect | 12,000,000 | 15.11 | $181.32M | 61,822,952 | Form 4 |
| 2025-08-22 | Rutz Michael PPresident of Sterigenics | Sale | 126,611 | 16.38 | $2.07M | 450,204 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
30 × grant or award25 × shares withheld for tax4 × option exercise2 × gift
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-05 | Lyons Jonathan M.Sr. Vice President, CFO | Shares withheld for tax F | −11,316 | 17.98 | 217,304 | Form 4 |
| 2026-05-26 | Shader AltonDirector, Chief Executive Officer | Grant or award A | +375,939 | – | 375,939 | Form 4 |
| 2026-05-26 | Shader AltonDirector, Chief Executive Officer | Grant or award A | +203,634 | – | 579,573 | Form 4 |
| 2026-05-22 | Wheadon David E.Director | Grant or award A | +14,970 | – | 89,882 | Form 4 |
| 2026-05-22 | Simon, ChristopherDirector | Grant or award A | +14,970 | – | 34,102 | Form 4 |
| 2026-05-22 | Chen RuoxiDirector | Grant or award A | +14,970 | – | 95,751 | Form 4 |
| 2026-05-22 | Petrella Vincent KDirector | Grant or award A | +14,970 | – | 95,751 | Form 4 |
| 2026-05-22 | Neary JamesDirector | Grant or award A | +14,970 | – | 95,751 | Form 4 |
| 2026-05-22 | Flynn KarenDirector | Grant or award A | +14,970 | – | 54,191 | Form 4 |
| 2026-05-22 | Cunningham Sean LaurenceDirector | Grant or award A | +14,970 | – | 95,751 | Form 4 |
| 2026-05-22 | Krause Kenneth D.Director | Grant or award A | +14,970 | – | 14,970 | Form 4 |
| 2026-05-22 | Kyle Richard GDirector | Grant or award A | +14,970 | – | 14,970 | Form 4 |
| 2026-05-22 | Klee Ann R.Director | Grant or award A | +14,970 | – | 140,926 | Form 4 |
| 2026-03-31 | Dimitrief AlexanderFormer SVP, GC and Sec. | Shares withheld for tax F | −7,941 | 14.34 | 312,040 | Form 4 |
| 2026-03-02 | Rutz Michael PPresident of Sterigenics | Shares withheld for tax F | −3,729 | 15.91 | 446,475 | Form 4 |
| 2026-03-02 | Rutz Michael PPresident of Sterigenics | Shares withheld for tax F | −4,495 | 15.91 | 441,980 | Form 4 |
| 2026-03-02 | Rutz Michael PPresident of Sterigenics | Option exercise M | +14,573 | – | 456,553 | Form 4 |
| 2026-03-02 | Rutz Michael PPresident of Sterigenics | Shares withheld for tax F | −17,497 | 15.91 | 439,056 | Form 4 |
| 2026-03-02 | Rutz Michael PPresident of Sterigenics | Grant or award A | +45,223 | – | 484,279 | Form 4 |
| 2026-03-02 | Lyons Jonathan M.Sr. Vice President, CFO | Shares withheld for tax F | −6,046 | 15.91 | 183,556 | Form 4 |
| 2026-03-02 | Lyons Jonathan M.Sr. Vice President, CFO | Option exercise M | +17,937 | – | 201,493 | Form 4 |
| 2026-03-02 | Lyons Jonathan M.Sr. Vice President, CFO | Shares withheld for tax F | −23,988 | 15.91 | 177,505 | Form 4 |
| 2026-03-02 | Lyons Jonathan M.Sr. Vice President, CFO | Shares withheld for tax F | −8,240 | 15.91 | 169,265 | Form 4 |
| 2026-03-02 | Lyons Jonathan M.Sr. Vice President, CFO | Grant or award A | +59,355 | – | 228,620 | Form 4 |
| 2026-03-02 | Dimitrief AlexanderSVP, General Counsel and Sec. | Shares withheld for tax F | −7,941 | 15.91 | 326,784 | Form 4 |
| 2026-03-02 | Dimitrief AlexanderSVP, General Counsel and Sec. | Option exercise M | +16,816 | – | 343,600 | Form 4 |
| 2026-03-02 | Dimitrief AlexanderSVP, General Counsel and Sec. | Shares withheld for tax F | −23,619 | 15.91 | 319,981 | Form 4 |
| 2026-03-02 | Petras Michael B. Jr.Director, Chairman & CEO | Shares withheld for tax F | −31,339 | 15.91 | 521,451 | Form 4 |
| 2026-03-02 | Petras Michael B. Jr.Director, Chairman & CEO | Shares withheld for tax F | −40,302 | 15.91 | 481,149 | Form 4 |
| 2026-03-02 | Petras Michael B. Jr.Director, Chairman & CEO | Option exercise M | +89,686 | – | 570,835 | Form 4 |
| 2026-03-02 | Petras Michael B. Jr.Director, Chairman & CEO | Shares withheld for tax F | −39,552 | 15.91 | 531,283 | Form 4 |
| 2026-03-02 | Petras Michael B. Jr.Director, Chairman & CEO | Shares withheld for tax F | −79,104 | 15.91 | 452,179 | Form 4 |
| 2026-03-02 | Petras Michael B. Jr.Director, Chairman & CEO | Grant or award A | +240,248 | – | 692,427 | Form 4 |
| 2025-08-05 | Lyons Jonathan M.Sr. Vice President, CFO | Shares withheld for tax F | −11,508 | 11.19 | 189,602 | Form 4 |
| 2025-05-22 | Simon, ChristopherDirector | Grant or award A | +19,132 | – | 19,132 | Form 4 |
| 2025-05-22 | Chen RuoxiDirector | Grant or award A | +19,132 | – | 80,781 | Form 4 |
| 2025-05-22 | Cunningham Sean LaurenceDirector | Grant or award A | +19,132 | – | 80,781 | Form 4 |
| 2025-05-22 | Klee Ann R.Director | Grant or award A | +19,132 | – | 125,956 | Form 4 |
| 2025-05-22 | Mihas Constantine SDirector | Grant or award A | +19,132 | – | 80,781 | Form 4 |
| 2025-05-22 | Neary JamesDirector | Grant or award A | +19,132 | – | 80,781 | Form 4 |
| 2025-05-22 | Petrella Vincent KDirector | Grant or award A | +19,132 | – | 80,781 | Form 4 |
| 2025-05-22 | Wheadon David E.Director | Grant or award A | +19,132 | – | 74,912 | Form 4 |
| 2025-05-22 | Knauss Robert BrownDirector | Grant or award A | +19,132 | – | 54,933 | Form 4 |
| 2025-05-22 | Flynn KarenDirector | Grant or award A | +19,132 | – | 39,221 | Form 4 |
| 2025-03-03 | Dimitrief AlexanderSVP, General Counsel and Sec. | Grant or award A | +56,053 | – | 334,725 | Form 4 |
| 2025-03-03 | Lyons Jonathan M.Sr. Vice President, CFO | Grant or award A | +59,790 | – | 163,741 | Form 4 |
| 2025-03-03 | Lyons Jonathan M.Sr. Vice President, CFO | Grant or award A | +37,369 | – | 201,110 | Form 4 |
| 2025-03-03 | Rutz Michael PPresident of Sterigenics | Grant or award A | +48,579 | – | 576,815 | Form 4 |
| 2025-03-03 | Petras Michael B. Jr.Director, Chairman & CEO | Grant or award A | +298,953 | – | 868,603 | Form 4 |
| 2025-03-02 | Dimitrief AlexanderSVP, General Counsel and Sec. | Shares withheld for tax F | −8,211 | 12.47 | 278,672 | Form 4 |
| 2025-03-02 | Lyons Jonathan M.Sr. Vice President, CFO | Shares withheld for tax F | −6,481 | 12.47 | 103,951 | Form 4 |
| 2025-03-02 | Rutz Michael PPresident of Sterigenics | Shares withheld for tax F | −3,687 | 12.47 | 537,833 | Form 4 |
| 2025-03-02 | Rutz Michael PPresident of Sterigenics | Shares withheld for tax F | −4,198 | 12.47 | 533,635 | Form 4 |
| 2025-03-02 | Rutz Michael PPresident of Sterigenics | Shares withheld for tax F | −5,399 | 12.47 | 528,236 | Form 4 |
| 2025-03-02 | Petras Michael B. Jr.Director, Chairman & CEO | Shares withheld for tax F | −27,990 | 12.47 | 642,509 | Form 4 |
| 2025-03-02 | Petras Michael B. Jr.Director, Chairman & CEO | Shares withheld for tax F | −31,872 | 12.47 | 610,637 | Form 4 |
| 2025-03-02 | Petras Michael B. Jr.Director, Chairman & CEO | Shares withheld for tax F | −40,987 | 12.47 | 569,650 | Form 4 |
| 2024-11-22 | Petras Michael B. Jr.Chairman & CEO | Gift G | −39,243 | – | 5,214,337 | Form 4 |
| 2024-11-22 | Petras Michael B. Jr.Chairman & CEO | Gift G | +39,243 | – | 39,243 | Form 4 |
| 2024-11-20 | Rutz Michael PPresident of Sterigenics | Shares withheld for tax F | −2,889 | 13.21 | 541,520 | Form 4 |
| 2024-11-20 | Petras Michael B. Jr.Chairman & CEO | Shares withheld for tax F | −29,250 | 13.21 | 670,499 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.